Dashboard
Manage Tickers

CRVO CervoMed Inc.

Nasdaq www.cervomed.com


$ 7.30 $ 0.32 (4.56 %)    

Wednesday, 05-Nov-2025 17:23:50 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 622.38 $ 4.94 (0.8 %)
DIA $ 473.04 $ 2.23 (0.47 %)
SPY $ 677.28 $ 2.47 (0.37 %)
TLT $ 89.01 $ -0.57 (-0.64 %)
GLD $ 365.20 $ 0.10 (0.03 %)
$ 7.34
$ 7.54
$ 6.78 x 250
$ 7.99 x 1
$ 7.06 - $ 7.78
$ 1.80 - $ 16.94
98,572
na
67.91M
$ -0.17
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2025 06-30-2025 10-Q
2 05-12-2025 03-31-2025 10-Q
3 03-17-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-09-2024 06-30-2024 10-Q
6 05-14-2024 03-31-2024 10-Q
7 03-29-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-08-2023 06-30-2023 10-Q
10 05-15-2023 03-31-2023 10-Q
11 03-24-2023 12-31-2022 10-K
12 11-14-2022 09-30-2022 10-Q
13 08-12-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-18-2022 12-31-2021 10-K
16 11-10-2021 09-30-2021 10-Q
17 08-11-2021 06-30-2021 10-Q
18 05-07-2021 03-31-2021 10-Q
19 03-17-2021 12-31-2020 10-K
20 11-12-2020 09-30-2020 10-Q
21 08-07-2020 06-30-2020 10-Q
22 05-11-2020 03-31-2020 10-Q
23 03-17-2020 12-31-2019 10-K
24 11-08-2019 09-30-2019 10-Q
25 08-08-2019 06-30-2019 10-Q
26 05-09-2019 03-31-2019 10-Q
27 03-19-2019 12-31-2018 10-K
28 11-13-2018 09-30-2018 10-Q
29 08-10-2018 06-30-2018 10-Q
30 05-10-2018 03-31-2018 10-Q
31 04-02-2018 12-31-2017 10-K
32 11-13-2017 09-30-2017 10-Q
33 08-14-2017 06-30-2017 10-Q
34 05-15-2017 03-31-2017 10-Q
35 03-31-2017 12-31-2016 10-K
36 11-14-2016 09-30-2016 10-Q
37 08-15-2016 06-30-2016 10-Q
38 05-16-2016 03-31-2016 10-Q
39 03-25-2016 12-31-2015 10-K
40 11-12-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

this-docebo-analyst-begins-coverage-on-a-bullish-note-here-are-top-3-initiations-for-wednesday
This Docebo Analyst Begins Coverage On A B...
11/05/2025 13:48:58

this-trex-company-analyst-turns-bearish-here-are-top-5-downgrades-for-wednesday
This Trex Company Analyst Turns Bearish; H...
11/05/2025 12:22:37

this-sarepta-therapeutics-analyst-turns-bullish-here-are-top-5-upgrades-for-wednesday
This Sarepta Therapeutics Analyst Turns Bu...
11/05/2025 11:44:29

hc-wainwright--co-upgrades-cervomed-to-buy-raises-price-target-to-25
HC Wainwright & Co. Upgrades CervoMed to B...
11/05/2025 11:35:54

HC Wainwright & Co. analyst Raghuram Selvaraju upgrades CervoMed (NASDAQ:CRVO) from Neutral to Buy and raises the price ...

d-boral-capital-maintains-buy-on-cervomed-maintains-31-price-target
D. Boral Capital Maintains Buy on CervoMed...
11/04/2025 13:41:57

D. Boral Capital analyst Jason Kolbert maintains CervoMed (NASDAQ:CRVO) with a Buy and maintains $31 price target.

cervomed-announces-fda-alignment-on-key-aspects-of-phase-3-neflamapimod-trial-in-dementia-with-lewy-bodies
CervoMed Announces FDA Alignment On Key As...
11/04/2025 12:12:50

cervomed-drug-cut-dementia-progression-risk-by-75-in-trial
CervoMed Drug Cut Dementia Progression Ris...
10/08/2025 15:54:18

CervoMed's Phase 2b trial shows neflamapimod reduces dementia progression and plasma GFAP, with significant cognitive impro...

cervomed-shares-additional-data-from-phase-2b-rewind-lb-trial-further-demonstrating-neflamapimods-potential-for-dementia-with-lewy-bodies
CervoMed Shares Additional Data From Phase...
10/08/2025 11:03:59

Significant improvement relative to placebo on primary outcome measure, change in Clinical Dementia Rating Sum of Boxes (CDR-SB...

cervomed-highlights-dementia-drug-results-at-major-neurology-conference
CervoMed Highlights Dementia Drug Results ...
09/17/2025 11:42:08

CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (Ce...

hc-wainwright--co-reiterates-neutral-on-cervomed-announces-11-price-target
HC Wainwright & Co. Reiterates Neutral on ...
09/08/2025 10:55:36

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates CervoMed (NASDAQ:CRVO) with a Neutral and announces $11 price ...

d-boral-capital-maintains-buy-on-cervomed-raises-price-target-to-31
D. Boral Capital Maintains Buy on CervoMed...
08/18/2025 11:45:07

D. Boral Capital analyst Jason Kolbert maintains CervoMed (NASDAQ:CRVO) with a Buy and raises the price target from $15 to $31.

roth-capital-reiterates-buy-on-cervomed-lowers-price-target-to-16
Roth Capital Reiterates Buy on CervoMed, L...
08/12/2025 17:32:23

Roth Capital analyst Boobalan Pachaiyappan reiterates CervoMed (NASDAQ:CRVO) with a Buy and lowers the price target from $20...

chardan-capital-maintains-buy-on-cervomed-maintains-15-price-target
Chardan Capital Maintains Buy on CervoMed,...
08/11/2025 11:46:25

Chardan Capital analyst Daniil Gataulin maintains CervoMed (NASDAQ:CRVO) with a Buy and maintains $15 price target.

cervomed-q2-eps-070-misses-063-estimate-sales-1758m-beat-1734m-estimate
CervoMed Q2 EPS $(0.70) Misses $(0.63) Est...
08/08/2025 13:57:44

CervoMed (NASDAQ:CRVO) reported quarterly losses of $(0.70) per share which missed the analyst consensus estimate of $(0.63) by...

canaccord-genuity-maintains-buy-on-cervomed-raises-price-target-to-27
Canaccord Genuity Maintains Buy on CervoMe...
07/29/2025 15:42:13

Canaccord Genuity analyst Sumant Kulkarni maintains CervoMed (NASDAQ:CRVO) with a Buy and raises the price target from $21 t...

cervomeds-dementia-data-show-slowed-disease-progression
CervoMed's Dementia Data Show Slowed Disea...
07/28/2025 15:20:34

CervoMed reports 32-week data showing neflamapimod slowed DLB progression and reduced neurodegeneration biomarkers with good to...

d-boral-capital-maintains-buy-on-cervomed-maintains-10-price-target
D. Boral Capital Maintains Buy on CervoMed...
07/28/2025 12:11:05

D. Boral Capital analyst Jason Kolbert maintains CervoMed (NASDAQ:CRVO) with a Buy and maintains $10 price target.

Core News & Articles
12 Health Care Stocks Moving In Monday's P...
07/28/2025 12:08:27

cervomed-shares-resume-trading-up-60-following-results-of-dementia-treatment-study
CervoMed Shares Resume Trading; Up 60% Fol...
07/28/2025 11:42:42

cervomed-announces-32-week-extension-results-from-phase-2b-rewind-lb-trial-of-oral-neflamapimod-in-dlb-indicating-continued-slowing-of-disease-progression-and-biomarker-activity
CervoMed Announces 32-Week Extension Resul...
07/28/2025 11:02:38

Based on the primary endpoint of Clinical Dementia Rating Sum of Boxes (CDR-SB), patients treated with neflamapimod showed 54% ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION